The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The ...
Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...
A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...
Skipping your dose to over-indulge could leave you “excusing yourself from the table in a hurry,” an expert tells PEOPLE ...
Huel, the meal replacement maker known for powdered food and “ready to drink” shakes, has posted a surge in profits as it ...
The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...
The claims were circulating on X, formerly known as Twitter, by commenters who were citing them as evidence of an alleged ...
GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.
Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...
The two drugs are metformin, one of the most widely used diabetes medications, and the GLP-1 class of medications that ...
Findings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...
Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback